Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder

Abstract

Treprostinil palmitil (TP), a prodrug of treprostinil, is being developed as an inhalation powder (TPIP) for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD). In ongoing human clinical trials, TPIP is administered via a commercially available high resistance (HR) RS01 capsule-based dry powder inhaler (DPI) device manufactured by Berry Global (formerly Plastiape), which utilizes the patient’s inspiratory flow to provide the required energy to deagglomerate and disperse the powder for delivery to their lungs. In this study, we characterized the aerosol performance of TPIP in response to changes in inhalation profiles to model more realistic use scenarios, i.e., for reduced inspiratory volumes and with inhalation acceleration rates that differ from those described in the compendia. The emitted dose of TP for all combinations of inhalation profiles and volumes ranged narrowly between 79 and 89% for the 16 and 32 mg TPIP capsules at the 60 LPM inspiratory flow rate but was reduced to 72–76% for the 16 mg TPIP capsule under the scenarios at the 30 LPM peak inspiratory flow rate. There were no meaningful differences in the fine particle dose (FPD) at all conditions at 60 LPM with the 4 L inhalation volume. The FPD values for the 16 mg TPIP capsule ranged narrowly between 60 and 65% of the loaded dose for all inhalation ramp rates with a 4 L volume and at both extremes of ramp rates for inhalation volumes down to 1 L, while the FPD values for the 32 mg TPIP capsule ranged between 53 and 65% of the loaded dose for all inhalation ramp rates with a 4 L volume and at both extremes of ramp rates for inhalation volumes down to 1 L for the 60 LPM flow rate. At the 30 LPM peak flow rate, the FPD values for the 16 mg TPIP capsule ranged narrowly between 54 and 58% of the loaded dose at both extremes of the ramp rates for inhalation volumes down to 1 L. Based on these in vitro findings, the TPIP delivery system appears not to be affected by the changes in inspiratory flow profiles or inspiratory volumes that might be expected to occur in patients with PAH or PH associated with underlying lung conditions such as ILD.

Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review

“…Since FDA approval, several formulations of treprostinil have been developed, including inhalation and capsule-based dry powder inhaler (DPI) devices 48. DPI devices, similar to well-known devices for asthma and COPD, could enhance patients’ comfort and thus improve compliance.…”

“…DPI devices, similar to well-known devices for asthma and COPD, could enhance patients’ comfort and thus improve compliance. It has been demonstrated that even with lower inhaled volumes and peak inspiratory flows, the administration of fine particles is acceptable 48 49. Moreover, a new pro-drug formulation, treprostinil palmitate, has recently been tested, resulting in fewer AEs and a more sustained effect 48 49…”

“…Since FDA approval, several formulations of treprostinil have been developed, including inhalation and capsulebased dry powder inhaler (DPI) devices. 48 DPI devices, similar to well-known devices for asthma and COPD, could enhance patients' comfort and thus improve compliance. It has been demonstrated that even with lower inhaled volumes and peak inspiratory flows, the administration of fine particles is acceptable.…”